Mackenzie Financial Corp Neurocrine Biosciences Inc Transaction History

Mackenzie Financial Corp

  • $65.9 Billion
  • Q1 2025

A detailed history of Mackenzie Financial Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Mackenzie Financial Corp holds 86,109 shares of NBIX stock, worth $10.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
86,109
Previous 55,221 55.94%
Holding current value
$10.6 Million
Previous $7.54 Million 26.35%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 07, 2025
BUY
$107.22 - $153.29 $3.31 Million - $4.73 Million
30,888 Added 55.94%
86,109 $9.52 Million
Q4 2024

Feb 14, 2025
SELL
$111.62 - $139.44 $3.5 Million - $4.37 Million
-31,362 Reduced 36.22%
55,221 $7.54 Million
Q3 2024

Nov 13, 2024
SELL
$114.58 - $153.15 $257,117 - $343,668
-2,244 Reduced 2.53%
86,583 $9.97 Million
Q2 2024

Aug 14, 2024
SELL
$130.86 - $143.19 $390,355 - $427,135
-2,983 Reduced 3.25%
88,827 $12.2 Million
Q1 2024

May 10, 2024
SELL
$130.4 - $143.74 $657,868 - $725,168
-5,045 Reduced 5.21%
91,810 $12.7 Million
Q4 2023

Jan 30, 2024
BUY
$106.07 - $132.76 $129,829 - $162,498
1,224 Added 1.28%
96,855 $12.8 Million
Q3 2023

Oct 25, 2023
BUY
$94.02 - $117.1 $308,103 - $383,736
3,277 Added 3.55%
95,631 $10.8 Million
Q2 2023

Aug 03, 2023
BUY
$89.53 - $104.87 $3.94 Million - $4.62 Million
44,056 Added 91.22%
92,354 $8.71 Million
Q1 2023

Apr 24, 2023
BUY
$94.11 - $123.02 $830,897 - $1.09 Million
8,829 Added 22.37%
48,298 $4.89 Million
Q4 2022

Feb 14, 2023
BUY
$106.72 - $127.06 $427,520 - $509,002
4,006 Added 11.3%
39,469 $4.71 Million
Q3 2022

Oct 07, 2022
SELL
$92.03 - $107.81 $706,146 - $827,226
-7,673 Reduced 17.79%
35,463 $3.77 Million
Q2 2022

Aug 10, 2022
BUY
$75.79 - $100.07 $1 Million - $1.32 Million
13,240 Added 44.29%
43,136 $4.21 Million
Q1 2022

May 13, 2022
BUY
$72.45 - $94.81 $1.43 Million - $1.87 Million
19,703 Added 193.3%
29,896 $2.8 Million
Q4 2021

Feb 14, 2022
SELL
$79.65 - $106.22 $361,053 - $481,495
-4,533 Reduced 30.78%
10,193 $868,000
Q3 2021

Nov 08, 2021
BUY
$86.18 - $99.03 $432,365 - $496,833
5,017 Added 51.67%
14,726 $1.41 Million
Q2 2021

Aug 11, 2021
SELL
$89.43 - $102.27 $12,162 - $13,908
-136 Reduced 1.38%
9,709 $945,000
Q1 2021

May 14, 2021
SELL
$87.57 - $119.4 $640,837 - $873,769
-7,318 Reduced 42.64%
9,845 $957,000
Q4 2020

Feb 10, 2021
BUY
$86.91 - $108.33 $68,224 - $85,039
785 Added 4.79%
17,163 $1.65 Million
Q3 2020

Nov 13, 2020
BUY
$96.16 - $135.15 $773,511 - $1.09 Million
8,044 Added 96.52%
16,378 $1.58 Million
Q2 2020

Aug 13, 2020
BUY
$85.09 - $130.36 $67,986 - $104,157
799 Added 10.6%
8,334 $1.02 Million
Q1 2020

May 14, 2020
SELL
$75.11 - $113.76 $3,455 - $5,232
-46 Reduced 0.61%
7,535 $652,000
Q4 2019

Feb 13, 2020
SELL
$86.8 - $118.57 $107,718 - $147,145
-1,241 Reduced 14.07%
7,581 $815,000
Q3 2019

Nov 14, 2019
BUY
$83.82 - $101.5 $131,765 - $159,558
1,572 Added 21.68%
8,822 $795,000
Q2 2019

Aug 14, 2019
SELL
$72.24 - $91.27 $104,314 - $131,793
-1,444 Reduced 16.61%
7,250 $612,000
Q1 2019

May 15, 2019
BUY
$69.31 - $91.53 $84,904 - $112,124
1,225 Added 16.4%
8,694 $766,000
Q4 2018

Feb 06, 2019
BUY
$68.32 - $124.36 $115,050 - $209,422
1,684 Added 29.11%
7,469 $533,000
Q3 2018

Nov 15, 2018
BUY
$98.88 - $125.85 $291,794 - $371,383
2,951 Added 104.13%
5,785 $711,000
Q2 2018

Aug 13, 2018
SELL
$75.3 - $105.99 $54,366 - $76,524
-722 Reduced 20.3%
2,834 $278,000
Q1 2018

May 14, 2018
BUY
$75.88 - $92.43 $269,829 - $328,681
3,556 New
3,556 $295,000

Others Institutions Holding NBIX

# of Institutions
650
Shares Held
97.2M
Call Options Held
749K
Put Options Held
553K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email